Table 3.
Recent case reports and case series evaluating treatment in metastatic anal cancer
| Study | n | Characteristics of patients | Regimen | Response | Survival |
| Jhawer et al[71], 2006 | 20Phase II | MMC, adriamycin, cisplatin followed by bleomycin-CCNU upon progression of disease | 60% PR0% CR | 15 mo | |
| Golub et al[67], 2011 | 3P1P2P3 | Previously treated with 5-FU and cisplatin | Paclitaxel 175 mg/m2 on D1Ifosfamide 1 g/m2 D1 to D4Cisplatin 75 mg/m2 on D1Every 3 wk | CR in 3 patientsResponse duration6 mo2.5 yr4 mo | Survival since recurrence14 mo30 mo17 mo (patient still alive) |
| Abbas et al[69], 2011 | 7 | Prior progression on cisplatin and 5-FU | Weekly paclitaxel | 1 CR, 3PR,1 SD | 12-14 mo1 |
| Kim et al[70], 2013 | 8 | Advanced recurrent | Docetaxel 75 mg/m2 day 1, CDDP 75 mg/m2 day 1 and 5-FU at 750 mg/m(2)/day for 5 d every 3 wk | CR: 50% | OS 62.5% at 12 mo |
| Khawandanah et al[68], 2014 | 1 | Skin and perianal metastasis | (1) Paclitaxel, ifosfamide, cisplatin (4 cycles) followed by(2) Mitomycin, cetuximab (2 cycles) | (1) Minimal residual disease(2) Mixed response | (1) Progression 5 mo after the end of therapy(2) OS 24 mo; 16 mo after paclitaxel was started |
| Barmettler et al[45], 2012 | 1 | Liver metastasis, KRAS wild type and EGFR 2 + | FOLFIRI + cetuximab | Partial response after 6 cycles | 21 mo |
| Bamba et al[46], 2012 | 1 | Lung metastasis | 3 FOLFOX→3 courses of FOLFOX + panitumumab→5 courses of FOLFIRI + panitumumab | Marked reduction of primary tumor, disappearance of lung metastasis. | The patient underwent low anterior resection.No recurrence after 5 mo |
| Lukan et al[47], 2009Case report | 7 | First or subsequent treatment line | Cetuximab alone or with irinotecan first or subsequent line. KRAS mutated in 2/7 | PR 3MR 1PD 2 (Mutated kras)SD 1 | NA |
| Nitori et al[72], 2011 | 1 | 58-yr-old female | Oral S-1 (120 mg/body; day 1-21) + low dose cisplatin (10 mg/body; day 1-5, 8-12) + RT for 2 cycles then rest for 4 wk | CR of the primary lesion and PR for the metastatic lesions | 16 mo |
1
Duration of clinical benefit in SD and PR after the initiation of Paclitaxel: 4-6 mo. PD: Progressive disease; PR: Partial response; MR: Minor response; SD: Stable disease; NA: Not availiable.